Aura Biosciences announced that Carol Shields, MD, Director of the Ocular Oncology Service at the Wills Eye Hospital in Philadelphia, will present data from the phase 1b clinical safety study of AU-011 during a late-breaking session at the American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans, Nov. 11-14.
Light-activated AU-011, an investigational, first-in-class targeted therapy is in development for the treatment of ocular melanoma, a rare and life-threatening disease. The first patient in this study was dosed this past March by Dr. Shields at the Wills Eye Hospital.
Dr. Shields’ presentation, titled “A Phase 1b Clinical Safety Study of a Novel Tumor Targeted Therapy (AU-011) for the Treatment of Primary Choroidal Melanoma,” will take place on Saturday, Nov. 11, at 9:03 a.m. CT in The Great Hall, as part of the session, “Section XIII: Late Breaking Development – Part II.”
Additional information, including the presentation schedule, may be found in the AAO Mobile Meeting Guide.